Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

SIMPLE SUMMARY: This study focused on actionable genetic alterations (AGAs) subtypes and pathologic or genetic biomarkers influencing the efficacy of immune checkpoint inhibitor (ICI) therapy in a real-world setting. In advanced non-small cell lung cancer (NSCLC) patients, the response to ICI monoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Jun, Soojin, Park, Sehhoon, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Cho, Juhee, Jung, Hyun Ae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670305/
https://www.ncbi.nlm.nih.gov/pubmed/38001710
http://dx.doi.org/10.3390/cancers15225450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670305/
https://www.ncbi.nlm.nih.gov/pubmed/38001710
http://dx.doi.org/10.3390/cancers15225450

Ejemplares similares